Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study

被引：0
|
作者：
Seoyoung C. Kim
Robert J. Glynn
Jun Liu
Brendan M. Everett
Allison B. Goldfine
机构：
[1] Brigham and Women’s Hospital,Division of Pharmacoepidemiology and Pharmacoeconomics
[2] Brigham and Women’s Hospital,Division of Rheumatology, Allergy and Immunology
[3] Brigham and Women’s Hospital,Division of Cardiovascular Medicine
[4] Joslin Diabetes Center,Clinical Research
来源：
Acta Diabetologica | 2014年 / 51卷
关键词：
Dipeptidyl peptidase-4 inhibitor; Type 2 diabetes; Cardiovascular disease; Heart failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1015 / 1023
页数：8
相关论文
共 50 条
  • [41] Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study
    Pradhan, Richeek
    Azoulay, Laurent
    Platt, Robert W.
    Yu, Oriana H. Y.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 13 - 13
  • [42] Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study
    Kim, Seoyoung C.
    Schneeweiss, Sebastian
    Glynn, Robert J.
    Doherty, Michael
    Goldfine, Allison B.
    Solomon, Daniel H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (11) : 1968 - 1975
  • [43] Kidney and Cardiovascular Effectiveness of Empagliflozin Compared With Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes
    Edmonston, Daniel
    Mulder, Hillary
    Lydon, Elizabeth
    Chiswell, Karen
    Lampron, Zachary
    Shay, Christina
    Marsolo, Keith
    Jones, William Schuyler
    Butler, Javed
    Shah, Raj C.
    Chamberlain, Alanna M.
    Ford, Daniel E.
    Gordon, Howard S.
    Hwang, Wenke
    Chang, Alexander
    Rao, Ajaykumar
    Bosworth, Hayden B.
    Pagidipati, Neha
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 221 : 52 - 63
  • [44] Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study
    Sheriza Baksh
    Jiajun Wen
    Omar Mansour
    Hsien-Yen Chang
    Mara McAdams-DeMarco
    Jodi B. Segal
    Stephan Ehrhardt
    G. Caleb Alexander
    Scientific Reports, 11
  • [45] Dipeptidyl Peptidase-4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes: A population-based cohort study
    Douros, Antonios
    Rouette, Julie
    Yin, Hui
    Yu, Oriana Hoi Yun
    Filion, Kristian B.
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 225 - 226
  • [46] Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus A Population-Based Cohort Study
    Kim, Young-Gun
    Yoon, Dukyong
    Park, Sooyoung
    Han, Seung Jin
    Kim, Dae Jung
    Lee, Kwan-Woo
    Park, Rae Woong
    Kim, Hae Jin
    CIRCULATION-HEART FAILURE, 2017, 10 (09)
  • [47] Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes in Taiwan A Population-Based Cohort Study
    Lai, Yun-Ju
    Hu, Hsiao-Yun
    Chen, Hsin-Hua
    Chou, Pesus
    MEDICINE, 2015, 94 (43)
  • [48] Dipeptidyl Peptidase-4 Inhibitors in Diverse Patient Populations With Type 2 Diabetes
    Hinnen, Deborah
    DIABETES EDUCATOR, 2015, 41 : 19S - 31S
  • [49] Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
    Deacon, C. F.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 7 - 18
  • [50] Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
    Richter, Bernd
    Bandeira-Echtler, Elizabeth
    Bergerhoff, Karla
    Lerch, Christian
    VASCULAR HEALTH AND RISK MANAGEMENT, 2008, 4 (04) : 753 - 768
12345